Guangdong Marubi Biotechnology Co., Ltd. (SHA:603983)
China · Delayed Price · Currency is CNY 32.55
-0.45 (-1.36%)
At close: Feb 6, 2026
SHA:603983 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,466 | 2,968 | 2,225 | 1,730 | 1,726 | 1,744 |
Other Revenue | 2.04 | 2.04 | 0.66 | 1.9 | 60.68 | 1.09 |
| 3,468 | 2,970 | 2,226 | 1,732 | 1,787 | 1,745 | |
Revenue Growth (YoY) | 31.28% | 33.44% | 28.52% | -3.09% | 2.41% | -3.10% |
Cost of Revenue | 912.63 | 793.26 | 665.27 | 557.04 | 654.5 | 595.69 |
Gross Profit | 2,555 | 2,177 | 1,560 | 1,175 | 1,133 | 1,149 |
Selling, General & Admin | 2,117 | 1,743 | 1,307 | 957.43 | 841.66 | 642.71 |
Research & Development | 81.9 | 73.54 | 62.29 | 52.93 | 50.49 | 50.15 |
Other Operating Expenses | 30.17 | 20.53 | 17.88 | 24.1 | 23.33 | 18.45 |
Operating Expenses | 2,228 | 1,837 | 1,385 | 1,037 | 916.19 | 711.36 |
Operating Income | 326.97 | 339.19 | 175.31 | 137.59 | 216.34 | 437.94 |
Interest Expense | -8.55 | -9.86 | -6.63 | -3.24 | -1.02 | -1.13 |
Interest & Investment Income | 45.68 | 44.44 | 65.05 | 43.64 | 60.14 | 87.43 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0.02 | 0.06 | 1.74 | 7.78 |
Other Non Operating Income (Expenses) | -0.83 | -0.29 | -0.64 | 0.21 | -0.98 | -0.48 |
EBT Excluding Unusual Items | 363.27 | 373.47 | 233.12 | 178.26 | 276.22 | 531.54 |
Gain (Loss) on Sale of Investments | 20.85 | -0.98 | 70.98 | 5.29 | 0.61 | -2.57 |
Gain (Loss) on Sale of Assets | 0.3 | -0.29 | 0.45 | 0.28 | 0.42 | -0.03 |
Asset Writedown | 4.15 | - | - | - | -0.1 | - |
Other Unusual Items | 8.45 | 8.45 | 12.53 | 22.75 | 32.47 | 38.43 |
Pretax Income | 397.02 | 380.66 | 317.09 | 206.58 | 309.63 | 567.37 |
Income Tax Expense | 47.79 | 38.29 | 39.5 | 39.15 | 68.43 | 103.97 |
Earnings From Continuing Operations | 349.22 | 342.36 | 277.59 | 167.43 | 241.19 | 463.4 |
Minority Interest in Earnings | -2.51 | -0.74 | -18.17 | 6.75 | 6.73 | 1 |
Net Income | 346.72 | 341.63 | 259.42 | 174.18 | 247.92 | 464.4 |
Net Income to Common | 346.72 | 341.63 | 259.42 | 174.18 | 247.92 | 464.4 |
Net Income Growth | 6.88% | 31.69% | 48.93% | -29.74% | -46.62% | -9.81% |
Shares Outstanding (Basic) | 403 | 402 | 399 | 405 | 400 | 400 |
Shares Outstanding (Diluted) | 403 | 402 | 399 | 405 | 400 | 400 |
Shares Change (YoY) | 2.25% | 0.70% | -1.47% | 1.30% | -0.12% | 6.52% |
EPS (Basic) | 0.86 | 0.85 | 0.65 | 0.43 | 0.62 | 1.16 |
EPS (Diluted) | 0.86 | 0.85 | 0.65 | 0.43 | 0.62 | 1.16 |
EPS Growth | 4.53% | 30.77% | 51.16% | -30.64% | -46.55% | -15.33% |
Free Cash Flow | 158.75 | -15.85 | 83.98 | -62.47 | -124.62 | -386.57 |
Free Cash Flow Per Share | 0.39 | -0.04 | 0.21 | -0.15 | -0.31 | -0.97 |
Dividend Per Share | 0.750 | 0.750 | 0.520 | 0.250 | 0.190 | 0.350 |
Dividend Growth | -2.60% | 44.23% | 108.00% | 31.58% | -45.71% | -10.26% |
Gross Margin | 73.68% | 73.29% | 70.11% | 67.83% | 63.38% | 65.86% |
Operating Margin | 9.43% | 11.42% | 7.88% | 7.95% | 12.11% | 25.10% |
Profit Margin | 10.00% | 11.50% | 11.66% | 10.06% | 13.87% | 26.61% |
Free Cash Flow Margin | 4.58% | -0.53% | 3.77% | -3.61% | -6.97% | -22.15% |
EBITDA | 352.03 | 360.74 | 192.17 | 154.13 | 231.83 | 450.59 |
EBITDA Margin | 10.15% | 12.15% | 8.63% | 8.90% | 12.97% | 25.82% |
D&A For EBITDA | 25.07 | 21.55 | 16.86 | 16.54 | 15.49 | 12.65 |
EBIT | 326.97 | 339.19 | 175.31 | 137.59 | 216.34 | 437.94 |
EBIT Margin | 9.43% | 11.42% | 7.88% | 7.95% | 12.11% | 25.10% |
Effective Tax Rate | 12.04% | 10.06% | 12.46% | 18.95% | 22.10% | 18.32% |
Revenue as Reported | 3,468 | 2,970 | 2,226 | 1,732 | 1,787 | 1,745 |
Advertising Expenses | - | 1,354 | 956.67 | 656.1 | 544.22 | 423.54 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.